Status:
COMPLETED
Practice Effects and Amyloid Imaging Using 18F-PIB or Flutemetamol PET and FDG-PET
Lead Sponsor:
University of Utah
Conditions:
Alzheimer's Disease
Eligibility:
All Genders
65+ years
Phase:
PHASE2
Brief Summary
Alzheimer's disease (AD) is the most common cause of progressive cognitive decline in the United States. AD is characterized by severe impairments in learning, memory and other cognitive abilities tha...
Detailed Description
The overall objective of this companion study project is to study the biodistribution and binding of 18F-Flutemetamol using PET imaging in community-dwelling functionally intact elderly subjects. Unde...
Eligibility Criteria
Inclusion
- Subjects must be currently enrolled in an NIA-sponsored, community-based study of practice effects in non-demented adults age 65 and older living independently (NIA #5K23AG028417-05)
Exclusion
- History of neurological disease known to affect cognition (e.g., stroke, head injury with loss of consciousness of \>30 minutes, seizure disorder, demyelinating disorder, mental retardation, etc.)
- Dementia based on DSM-IV criteria
- Current or past major psychiatric illness (e.g., schizophrenia, bipolar affective disorder)
- 30-item Geriatric Depression Score \>14
- Evidence of stroke or mass lesion on CT or MRI scan
- History of alcoholism or other substance abuse
- Current use of cholinesterase inhibitors, other cognitive enhancers, antipsychotics, or anticonvulsant medications
- History of radiation therapy to the brain
- History of significant major medical illnesses, such as cancer or AIDS
- Uncontrolled diabetes or blood glucose \>180 mg/dl on the day of the FDG-PET scan
- Currently pregnant
Key Trial Info
Start Date :
May 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 14 2020
Estimated Enrollment :
27 Patients enrolled
Trial Details
Trial ID
NCT01202994
Start Date
May 1 2011
End Date
October 14 2020
Last Update
May 9 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Utah Center for Alzheimer's Care, Imaging and Research
Salt Lake City, Utah, United States, 84108